The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

Trial Profile

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Apalutamide (Primary) ; LHRH receptor agonists
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Aragon Pharmaceuticals; Johnson & Johnson
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 23 Mar 2015 Planned End Date changed from 1 Feb 2018 to 1 Jan 2020 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top